Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Trial Profile

Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors SCRI Development Innovations
  • Most Recent Events

    • 14 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 09 Oct 2015 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018 as per ClinicalTrials.gov record.
    • 09 Oct 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top